Fatih Kus

18PUBLICATIONS
122CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersMolecular targetsTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 15, 2026
Long-Term Outcomes and Prognostic Factors in Metastatic ALK-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center.

|Aug 13, 2026
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

|Jul 28, 2026
Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.

|Jun 26, 2026
Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

|Nov 27, 2025
KELIM PSA as a Prognostic Biomarker in Castration-Resistant Prostate Cancer Treated with ARPI.

Fatih Atalah, Fatih Kuş, Aydın Acarbay

|Nov 17, 2025
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

Pageof 3

Frequent Collaborators

7 joint publications

Hasan Çağrı Yıldırım

3 joint publications

Gokhan Sahin

3 joint publications

Zafer Arık

3 joint publications

Deniz Can Guven